yahoo_financeOriginal article
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X
Phase 2IHL-42XPositive
AI Analysis
Summary
Incannex announced the first patient dosing in the DReAMzz Phase 2 study of IHL-42X. This represents the initiation of clinical trial enrollment.
Clinical Trial Data
Phase
2
Outcome Details
First patient dosed in DReAMzz Phase 2 study
Importance:5/10
Sentiment:
0.30
Phase 2Clinical TrialTrial InitiationIHL-42X
Related Companies
Read the original article
Published by yahoo_finance on August 25, 2026 12:46 PM